文献速递免疫规划传染病防控与疫情报告

新型重组YidR蛋白疫苗抗肺炎克雷伯菌感染的开发与评价

Development and evaluation of a new recombinant protein vaccine (YidR) against Klebsiella pneumoniae infection.
PubMed 文献 · Vaccine · 2020-05-20

研究以高度保守的YidR蛋白为抗原,在大肠杆菌中重组表达并纯化,免疫小鼠后评估其对致死性肺炎克雷伯菌攻击的保护效果。结果显示免疫组血清总IgG显著升高,攻击后脓毒症更轻、体重更高,约90%免疫小鼠存活超过10天观察期,而对照组小鼠在48小时内全部死亡。

要点

  • YidR蛋白在肺炎克雷伯菌各血清型间高度保守,是潜在广谱疫苗抗原。
  • 重组YidR免疫可显著诱导血清总IgG抗体产生。
  • 致死剂量攻击后约90%免疫小鼠存活超过10天,对照组48小时内全部死亡。

核心结论

  • 重组YidR蛋白疫苗在小鼠模型中显示出对致死性肺炎克雷伯菌攻击的保护效果,YidR可能是预防克雷伯菌感染的候选疫苗抗原。

研究设计与样本

  • 研究将yidR基因克隆至大肠杆菌进行重组表达并纯化蛋白,测定肺炎克雷伯菌致死剂量(LD100),免疫小鼠后以LD100进行致死性攻击观察保护效果。

主要发现

  • YidR免疫小鼠血清总IgG浓度显著高于未免疫小鼠,表明可强效诱导抗体产生。
  • 以LD100肺炎克雷伯菌攻击后,YidR免疫小鼠较未免疫对照脓毒症显著更轻、体重更高。
  • 约90%的YidR免疫小鼠存活超过10天观察期,而对照小鼠无一存活超过48小时。

临床怎么用

  • 目前仅为小鼠模型证据,尚不能直接用于人群预防,需进一步开展临床前毒理与免疫原性研究。

局限性

  • 研究仅在小鼠模型中进行,未报告在人群或其他动物模型中的保护效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Vaccination is a promising approach to prevent Klebsiella infection; however, the high heterogeneity of strains is a limiting factor. The best antigenic target for an anti-Klebsiella vaccine should be expressed by all or most of strains. We previously found YidR protein to be highly conserved among K. pneumoniae strains independently of antigen serotype. Therefore, in the present study, we developed a recombinant YidR protein vaccine and evaluated its protective efficacy against lethal challenge with K. pneumoniae in a mouse model. The yidR gene was cloned in Escherichia coli for recombinant expression. The lethal dose (LD100) of K. pneumoniae was determined and lethal challenge was carried out after immunization with recombinant purified YidR. After immunization, the concentration of total serum IgG was significantly higher in YidR-immunized mice than in non-immunized mice, indicating strong induction of antibodies. Mice were challenged with LD100 of K. pneumoniae, and significantly lower murine sepsis and higher body weight were observed in YidR-immunized mice compared to unvaccinated controls. Moreover, ∼90% of YidR-immunized mice survived beyond 10 days of observation, whereas none of the control mice survived past 48 h. The protective effect of YidR recombinant protein vaccine was demonstrated and YidR may be a promising vaccine candidate to prevent klebsiellosis.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Rodrigues MX, Yang Y, de Souza Meira EB, et al. Development and evaluation of a new recombinant protein vaccine (YidR) against Klebsiella pneumoniae infection. Vaccine. 2020. PMID: 32444194. doi:10.1016/j.vaccine.2020.03.057

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。